Rentschler Biopharma SE

Activities: Pharmaceutical

Trending Articles

  1. Ingenza debuts Bacillus protein production system alternative to E. coli The Scottish CRDMO's new GenXpress Bacillus technology offers a highly productive alternative to the traditional E. coli expression systems that is free from endotoxins and...
  2. IMA Life-Sharp Sterile Manufacturing partnership strengthened with aseptic technology facility Sharp's expanded facility in Massachusetts will include the installation of a fully automated IMA Life isolated filling line for Ready-To-Use (RTU) vials, addressing demand for...
  3. FDA and EMA issue guiding principles for AI in drug development The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to...
  4. Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also...
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Miniaturisation in medtech: mechanical factors that influence product success Medical devices are becoming smaller, lighter and more portable. From handheld diagnostic tools to wearable infusion pumps and compact surgical instruments, reduced size is now...

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

Related Content

Research & Development

Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies

Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies
Manufacturing

Rentschler Biopharma and Coriolis Pharma partner to deliver integrated biopharma development and manufacturing solutions

The German-based CDMO and CRDO will offer unified formulation-to-manufacturing services to accelerate biologics development. The collaboration aims to cut complexity, timelines and risk for global biopharma clients
Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea

Rentschler Biopharma appoints Robert Panting as VP Global Client Program Management and Strategy

In this role, he will lead the company’s global Strategy initiatives and CPM functions, and he will be reporting directly to the CEO, serving as a member of the Global Leadership Team
Research & Development

Rentschler Biopharma appoints Patrick Meyer as Global Head of Business Development

Rentschler Biopharma SE, a leading global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, announced the promotion of Patrick Meyer, Ph.D., to Global Head of Business Development (BD), effective immediately
Manufacturing

Rentschler Biopharma begins construction on buffer media station for biologics manufacturing

The expansion will optimise the CDMO's process efficiency, while helping them to cater to global biopharmaceutical clients
Manufacturing

Rentschler Biopharma boosts UK end-to-end lentiviral vector manufacturing capabilities

The company can now develop and produce LVVs for the biopharmaceutical market, which have a high potential in treating a range of diseases
Subscribe now